Data Demonstrating Precede Biosciences’ Ability to Determine HER2 Status from 1mL of Plasma to be Presented at the 2023 San Antonio Breast Cancer Symposium

<p>BOSTON, Nov. 28, 2023 (GLOBE NEWSWIRE) — Precede Biosciences, a company impacting the development and use of precision medicines with a first-in-class liquid biopsy platform, announces that data supporting the use of its platform to determine HER2 status in patients with metastatic breast cancer will be presented at the 2023 San Antonio Breast Cancer Symposium […]</p>
<p>The post <a href="https://forextv.com/top-news/data-demonstrating-precede-biosciences-ability-to-determine-her2-status-from-1ml-of-plasma-to-be-presented-at-the-2023-san-antonio-breast-cancer-symposium/">Data Demonstrating Precede Biosciences’ Ability to Determine HER2 Status from 1mL of Plasma to be Presented at the 2023 San Antonio Breast Cancer Symposium</a> appeared first on <a href="https://forextv.com">ForexTV</a>.</p>